AMENDMENT NO. 4 TO PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 11th, 2021 • Moleculin Biotech, Inc. • Pharmaceutical preparations
This Amendment No. 4, effective as of the date fully executed by both Parties (“Amendment No. 4 Effective Date”), to that certain Patent and Technology License Agreement between the Parties dated April 2, 2012, as previously amended by Amendment No.1 dated October 19, 2015 and Amendment No. 2 dated November 1, 2018, and Amendment No. 3 dated May 20, 2020 (as so amended, the “Original License”), is made by and between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, on behalf of The University of Texas M. D. Anderson Cancer Center (hereinafter “UTMDACC”), a member institution of System, and Moleculin Biotech, Inc. (hereinafter “Licensee”), a Delaware corporation having a principal place of business located at 5300 Memorial Dr., Suite 950, Houston, Texas 77007. Board, on behalf of UTMDACC, and Licensee may herein be referred to collectively as the “Parties.”
INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification and Advancement Agreement • August 11th, 2021 • Moleculin Biotech, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of ___________, 2021, by and between Moleculin Biotech, Inc., a Delaware corporation (the “Company”), and _____________ (“Indemnitee”). Capitalized terms used but not otherwise defined herein have the meanings set forth in Section 12.
